中的时钟基因失调:一个系统的审查
Guilherme Fernandes-Campos1, Arjune Sen2, Francesca Panin1
1School of Life Sciences, Faculty of Science and Engineering, Anglia Ruskin University, Cambridge, UK.
Epilepsia open
|December 20, 2025
概括
时钟基因可能在中起着保护作用,尽管研究有限,结果相互矛盾. 需要进行进一步的研究,以了解它们在的昼夜模式中的作用.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 时间生物学 时间生物学
背景情况:
- 发作表现出时间模式,表明昼夜节律的参与.
- 时钟基因调节昼夜节律,并可能影响病理生理学.
研究的目的:
- 系统地审查时钟基因与病理生理学的关系.
- 综合当前关于症时钟基因参与的文献.
主要方法:
- 在主要的科学数据库 (Scopus,Embase,Medline,CINHAL,Web of Sciences) 进行系统的文献搜索.
- 包括来自6364项鉴定研究的26篇相关文章.
- 对检查钟基因淘汰,表达和变异的研究进行分析.
主要成果:
- 研究方法包括时钟基因淘汰效应,的表达水平和基因变异.
- 大多数研究表明,钟基因 (例如,Clock,Bmal1) 在中起着保护作用.
- 相互矛盾的结果和方法上的异质性限制了最终的结论;在人类病例中发现的一些时钟基因变异.
结论:
- 时钟基因和相互作用蛋白质的失调可能为的昼夜方面提供了洞察力.
- 需要进一步的研究,以澄清时钟基因功能障碍在中的确切影响.
相关概念视频
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Circadian Rhythms and Gene Regulation
4.5K
The biological clock is involved in many aspects of regulating complex physiology in all animals. It was in 1935 when German zoologists, Hans Kalmus and Erwin Bünning, discovered the existence of circadian rhythm in Drosophila melanogaster. However, the internal molecular mechanisms behind the circadian clock remained a mystery until 1984, when Jeffrey C. Hall, Michael Rosbash, and Michael W. Young discovered the expression of the Per gene oscillating over a 24-hour cycle. In subsequent...
4.5K
Seizures: Classification
1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
603
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
603
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
790
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
790


